{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T05:47:52Z","timestamp":1741153672652,"version":"3.38.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Exploratory Research in Clinical and Social Pharmacy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.rcsop.2024.100548","type":"journal-article","created":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T00:14:34Z","timestamp":1733616874000},"page":"100548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Drug utilisation research and medicine access in Mozambique: An overview"],"prefix":"10.1016","volume":"17","author":[{"given":"Roger","family":"Wiseman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilse","family":"Truter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"United Nations Human Rights","key":"10.1016\/j.rcsop.2024.100548_bb0005"},{"year":"2024","author":"United Nations","key":"10.1016\/j.rcsop.2024.100548_bb0010"},{"key":"10.1016\/j.rcsop.2024.100548_bb0015","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/heapol\/czz119","article-title":"Access to medicines through health systems in low- and middle-income countries","volume":"34","author":"Ozawa","year":"2019","journal-title":"Health Policy Plan"},{"key":"10.1016\/j.rcsop.2024.100548_bb0020","first-page":"27","article-title":"Problems in assessing rationality of drug utilization in less developed countries","volume":"721","author":"Ali","year":"1988","journal-title":"Acta Med Scand Suppl"},{"key":"10.1016\/j.rcsop.2024.100548_bb0025","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/bcpt.13136","article-title":"A review of the Ghana National Health Insurance Scheme claims database: possibilities and limits for drug utilization research","volume":"124","author":"Ankrah","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.rcsop.2024.100548_bb0030","series-title":"People's Health Movement","article-title":"Mozambique's health system is in turmoil","author":"People's Health Dispatch","year":"2023"},{"author":"World Bank","key":"10.1016\/j.rcsop.2024.100548_bb0035"},{"year":"2019","series-title":"Overview of private actors in the Mozambican health system and rapid assessment of the supply chain: technical report","author":"United States Agency for International Development (USAID)","key":"10.1016\/j.rcsop.2024.100548_bb0040"},{"author":"World Bank","key":"10.1016\/j.rcsop.2024.100548_bb0045"},{"key":"10.1016\/j.rcsop.2024.100548_bb0050","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1177\/1750698021995993","article-title":"Different mechanisms, same result: remembering the liberation war in Mozambique","volume":"14","author":"Bueno","year":"2021","journal-title":"Mem Stud"},{"author":"Central Intelligence Agency","key":"10.1016\/j.rcsop.2024.100548_bb0055"},{"author":"United Nations International Children's Emergency Fund (UNICEF)","key":"10.1016\/j.rcsop.2024.100548_bb0060"},{"key":"10.1016\/j.rcsop.2024.100548_bb0065","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/heapol\/czt031","article-title":"How to (or not to) \u2026 measure performance against the Abuja target for public health expenditure","volume":"29","author":"Witter","year":"2013","journal-title":"Health Policy Plan"},{"year":"2001","series-title":"Abuja declaration on HIV\/AIDS, tuberculosis and other related infectious diseases","author":"African Union","key":"10.1016\/j.rcsop.2024.100548_bb0070"},{"year":"1991","series-title":"Boletim da Rep\u00fablica; Publica\u00e7\u00e3o Oficial da Rep\u00fablica de Mo\u00e7ambique; Imprensa Nacional de Mo\u00e7ambique; I s\u00e9rie- N\u00famero 54","author":"Law No. 25\/1991","key":"10.1016\/j.rcsop.2024.100548_bb0075"},{"key":"10.1016\/j.rcsop.2024.100548_bb0080","doi-asserted-by":"crossref","DOI":"10.1590\/1518-8345.0995.2679","article-title":"Right to health: (in) congruence between the legal framework and the health system","volume":"24","author":"Mitano","year":"2016","journal-title":"Rev Lat Am Enfermagem"},{"year":"2016","series-title":"Health Financing Profile: Mozambique","author":"Health Policy Project","key":"10.1016\/j.rcsop.2024.100548_bb0085"},{"author":"Freiburghaus","key":"10.1016\/j.rcsop.2024.100548_bb0090"},{"year":"2019","series-title":"GLI \u2013 Pricing & Reimbursement 2019: Mozambique","author":"Paulouro","key":"10.1016\/j.rcsop.2024.100548_bb0095"},{"year":"2017","series-title":"Boletim da Rep\u00fablica; Publica\u00e7\u00e3o Oficial da Rep\u00fablica de Mo\u00e7ambique; Imprensa Nacional de Mo\u00e7ambique; I s\u00e9rie- N\u00famero 141","author":"Law No. 12\/2017","key":"10.1016\/j.rcsop.2024.100548_bb0100"},{"year":"2020","series-title":"Selection of Essential Medicines at Country Level: Using the WHO Model List of Essential Medicines to Update a National Essential Medicines List","author":"World Health Organization","key":"10.1016\/j.rcsop.2024.100548_bb0105"},{"key":"10.1016\/j.rcsop.2024.100548_bb0110","series-title":"Essential drugs in Mozambique","first-page":"26","author":"Hanlon","year":"1983"},{"year":"2018","series-title":"Mozambique End of Project Report. Submitted to the US Agency for International Development by the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program","author":"Systems for Improved Access to Pharmaceuticals and Services (SIAPS)","key":"10.1016\/j.rcsop.2024.100548_bb0115"},{"author":"Minist\u00e9rio da Sa\u00fade (MISAU)","key":"10.1016\/j.rcsop.2024.100548_bb0120"},{"year":"2023","series-title":"Boletim da Rep\u00fablica; Publica\u00e7\u00e3o Oficial da Rep\u00fablica de Mo\u00e7ambique; Imprensa Nacional de Mo\u00e7ambique; I s\u00e9rie- N\u00famero 52","author":"Ministerial Diploma No. 52\/2023","key":"10.1016\/j.rcsop.2024.100548_bb0125"},{"year":"1977","series-title":"Boletim da Rep\u00fablica; Publica\u00e7\u00e3o Oficial da Rep\u00fablica de Mo\u00e7ambique; Imprensa Nacional de Mo\u00e7ambique; I s\u00e9rie- N\u00famero 24","author":"Law No. 2\/1977","key":"10.1016\/j.rcsop.2024.100548_bb0130"},{"year":"1985","series-title":"Boletim da Rep\u00fablica; Publica\u00e7\u00e3o Oficial da Rep\u00fablica de Mo\u00e7ambique; Imprensa Nacional de Mo\u00e7ambique; I s\u00e9rie- N\u00famero 27","author":"Ministerial Diploma No. 24\/1985","key":"10.1016\/j.rcsop.2024.100548_bb0135"},{"key":"10.1016\/j.rcsop.2024.100548_bb0140","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1759-5436.1983.mp14004010.x","article-title":"Pharmaceutical policy in independent Mozambique: the first years","volume":"14","author":"Martins","year":"1983","journal-title":"IDS Bull"},{"key":"10.1016\/j.rcsop.2024.100548_bb0145","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/heapol\/czp042","article-title":"Medicine prices in urban Mozambique: a public health and economic study of pharmaceutical markets and price determinants in low-income settings","volume":"25","author":"Russo","year":"2010","journal-title":"Health Policy Plan"},{"year":"1990","series-title":"Boletim da Rep\u00fablica; Publica\u00e7\u00e3o Oficial da Rep\u00fablica de Mo\u00e7ambique; Imprensa Nacional de Mo\u00e7ambique; I s\u00e9rie- N\u00famero 52","author":"Ministerial Diploma No. 109\/1990","key":"10.1016\/j.rcsop.2024.100548_bb0150"},{"year":"2017","series-title":"Boletim da Rep\u00fablica; Publica\u00e7\u00e3o Oficial da Rep\u00fablica de Mo\u00e7ambique; Imprensa Nacional de Mo\u00e7ambique; I s\u00e9rie- N\u00famero 40","author":"Ministerial Diploma No. 21\/2017","key":"10.1016\/j.rcsop.2024.100548_bb0155"},{"key":"10.1016\/j.rcsop.2024.100548_bb0160","series-title":"Encyclopedia of Pharmacy Practice and Clinical Pharmacy","first-page":"445","article-title":"Application of Pharmacoepidemiology and pharmacovigilance studies","author":"Nishtala","year":"2019"},{"key":"10.1016\/j.rcsop.2024.100548_bb0165","series-title":"WHO Expert Committee: The Selection of Essential Drugs (Technical Report Series 615)","first-page":"1","author":"World Health Organization","year":"1977"},{"key":"10.1016\/j.rcsop.2024.100548_bb0170","series-title":"Pharmacoepidemiology and Therapeutic Risk Management","article-title":"Drug utilisation research","author":"Wettermark","year":"2008"},{"key":"10.1016\/j.rcsop.2024.100548_bb0175","series-title":"Drug Utilization Research: Methods and Applications","article-title":"Chapter 1: Introduction to drug utilization research","author":"Wettermark","year":"2016"},{"key":"10.1016\/j.rcsop.2024.100548_bb0180","first-page":"91","article-title":"A review of drug utilization studies and methodologies","volume":"1","author":"Truter","year":"2008","journal-title":"Jordan J Pharm Sci"},{"key":"10.1016\/j.rcsop.2024.100548_bb0185","series-title":"WHO Policies Perspectives on Medicines","article-title":"Promoting rational use of medicines: core components","author":"World Health Organization","year":"2002"},{"year":"2011","series-title":"The World Medicines Situation 2011: Rational Use of Medicines","author":"Holloway","key":"10.1016\/j.rcsop.2024.100548_bb0190"},{"key":"10.1016\/j.rcsop.2024.100548_bb0195","series-title":"MDS-3: Managing Access to Medicines and Health Technologies","article-title":"Chapter 29: promoting rational prescribing","author":"Chalker","year":"2012"},{"year":"2009","series-title":"Medicine Use in Primary Care in Developing and Transitional Countries","author":"World Health Organization","key":"10.1016\/j.rcsop.2024.100548_bb0200"},{"year":"2003","series-title":"Adherence to Long-Term Therapies: Evidence for Action","author":"World Health Organization","key":"10.1016\/j.rcsop.2024.100548_bb0205"},{"key":"10.1016\/j.rcsop.2024.100548_bb0210","series-title":"WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology & WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services","article-title":"Introduction to drug utilization research","author":"World Health Organization","year":"2003"},{"key":"10.1016\/j.rcsop.2024.100548_bb0215","series-title":"Studies in Drug Utilization","first-page":"17","article-title":"Chapter 2: the methodology of drug utilization studies","volume":"Vol. 8","author":"Lunde","year":"1979"}],"container-title":["Exploratory Research in Clinical and Social Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276624001458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276624001458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T21:52:38Z","timestamp":1741125158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667276624001458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":43,"alternative-id":["S2667276624001458"],"URL":"https:\/\/doi.org\/10.1016\/j.rcsop.2024.100548","relation":{},"ISSN":["2667-2766"],"issn-type":[{"type":"print","value":"2667-2766"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug utilisation research and medicine access in Mozambique: An overview","name":"articletitle","label":"Article Title"},{"value":"Exploratory Research in Clinical and Social Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rcsop.2024.100548","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100548"}}